News

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

Details

Immatics announced a clinical data update from the dose escalation cohorts of the company’s ongoing Phase 1 trials for its engineered Adoptive Cell Therapy approach (also known as TCR-T). 

Partner Therapeutics Announces Partnership with SIRS Therapeutics and F4 Pharma to Explore Potential Uses for FX06 in Biodefense Applications

Details

Partner Therapeutics, Inc. (PTx), announces a licensing and collaboration agreement with Munich-based SIRS Theraputics and Vienna-based F4 Pharma to support the development of FX-06, a synthetic peptide that has a broad spectrum of potential indications.  

eGenesis Announces $125 Million Series C Financing

Details

Proceeds will advance two lead xenotransplantation programs in kidney failure and type 1 diabetes into first-in-human studies. 

  1. Creative Balloons closes €15 million growth financing and appoints Frank Gehres as CEO
  2. ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury
  3. ONWARD Announces First Patient Enrolled in the Up-LIFT Pivotal Trial Assessing Safety and Effectiveness of ARC Therapy for Spinal Cord Injury
  4. Quanta Receives FDA 510(k) Clearance for the SC+ Hemodialysis System Setting the Stage for US Market Launch
© Wellington Partners, 2021.